Ability to Achieve a Good Eular Response in Patients With Moderate-to-severe Active Early Rheumatoid Arthritis Who Satisfy the New ACR/EULAR Classification Criteria Receiving Etanercept + MTX in Real World Clinical Practice in Greece

Trial Profile

Ability to Achieve a Good Eular Response in Patients With Moderate-to-severe Active Early Rheumatoid Arthritis Who Satisfy the New ACR/EULAR Classification Criteria Receiving Etanercept + MTX in Real World Clinical Practice in Greece

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Nov 2016

At a glance

  • Drugs Etanercept (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms EARLY RA
  • Sponsors Pfizer
  • Most Recent Events

    • 16 Jun 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
    • 14 May 2015 Planned End Date changed from 1 Apr 2015 to 1 May 2015, according to to ClinicalTrials.gov record.
    • 14 May 2015 Planned primary completion date changed from 1 Apr 2015 to 1 May 2015, according to to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top